HOXA1 upregulation is associated with poor prognosis and tumor progression in breast cancer.

HOXA1 upregulation is associated with poor prognosis and tumor progression in breast cancer. Exp Ther Med. 2019 Mar;17(3):1896-1902 Authors: Liu J, Liu J, Lu X Abstract Breast cancer (BC) is the most commonly diagnosed cancer and the second leading cause of cancer-associated mortality among females worldwide. As a member of the homeobox (HOX) gene family, HOXA1 is involved in tumor progression and prognosis in several types of human cancer. However, the clinical significance and biological functions of HOXA1 in BC remains unknown. The current study assessed the expression of HOXA1 in BC tissues and cells via western blotting and reverse transcription-quantitative polymerase chain reaction. The association between HOXA1 expression and the clinicopathological features of patients with BC was analyzed using the Chi-square test. The overall survival of patients was calculated using the Kaplan-Meier method and examined using the log-rank test. Cell proliferation was examined via an MTT assay. Cell cycle distribution and cell apoptosis were analyzed using flow cytometry. The current study demonstrated that HOXA1 mRNA and protein expression was upregulated in BC. In addition, HOXA1 overexpression was associated with poor prognosis and advanced clinicopathological features in patients with BC. Furthermore, knockdown of HOXA1 significantly inhibited cell proliferation by enhancing cell apoptosis and cell cycle arrest in BC cells, which was ac...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research